N.A. Beelen
Recente publicaties
-
Barbeau, L. M. O., Beelen, N. A., Savelkouls, K. G., Keulers, T. G. H., Wieten, L., & Rouschop, K. M. A. (2025). MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer. PLOS ONE, 20(2), Article e0316716. https://doi.org/10.1371/journal.pone.0316716Meer informative over deze publicatie
-
Beelen, N. A., Valckx, V. T. C., Bos, G. M. J., & Wieten, L. (2024). Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy. Best Practice & Research Clinical Haematology, 37(3), Article 101568. https://doi.org/10.1016/j.beha.2024.101568Meer informative over deze publicatie
-
Beelen, N. A., Molenbroeck, S. J. J., Groeneveld, L., Voorter, C. E., Bos, G. M. J., & Wieten, L. (2024). HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma. Immunogenetics, 76(3), 155-164. https://doi.org/10.1007/s00251-024-01336-wMeer informative over deze publicatie
-
Beelen, N. A. (2024). Natural killer cells in the tumor microenvironment: Enhancing immunotherapy by exploring the communication between NK cells and tumor cells. [Doctoral Thesis, Maastricht University]. Maastricht University. https://doi.org/10.26481/dis.20240426nbMeer informative over deze publicatie
-
Beelen, N. A., Aberle, M. R., Bruno, V., Olde Damink, S. W. M., Bos, G. M. J., Rensen, S. S., & Wieten, L. (2023). Antibody-dependent cellular cytotoxicity-inducing antibodies enhance the natural killer cell anti-cancer response against patient-derived pancreatic cancer organoids. Frontiers in Immunology, 14(1), Article 1133796. https://doi.org/10.3389/fimmu.2023.1133796Meer informative over deze publicatie
-
Beelen, N. A., Ehlers, F. A. I., Bos, G. M. J., & Wieten, L. (2023). Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Cancer Immunology Immunotherapy, 72(4), 797-804. https://doi.org/10.1007/s00262-022-03299-xMeer informative over deze publicatie
-
Beelen, N. A., Ehlers, F. A. I., Kooreman, L. F. S., Bos, G. M. J., & Wieten, L. (2023). An in vitro model to monitor natural killer cell effector functions against breast cancer cells derived from human tumor tissue. In C. Thomas, & L. Galluzzi (Eds.), The Immunological Synapse Part A (1 ed., Vol. 173, pp. 133-153). Academic Press. https://doi.org/10.1016/bs.mcb.2022.05.001Meer informative over deze publicatie
-
Beaumont, J. E. J., Beelen, N. A., Wieten, L., & Rouschop, K. M. A. (2022). The Immunomodulatory Role of Hypoxic Tumor-Derived Extracellular Vesicles. Cancers, 14(16), Article 4001. https://doi.org/10.3390/cancers14164001Meer informative over deze publicatie
-
Sheffer, M., Lowry, E., Beelen, N., Borah, M., Naffar-Abu Amara, S., Mader, C. C., Roth, J. A., Tsherniak, A., Freeman, S. S., Dashevsky, O., Gandolfi, S., Bender, S., Bryan, J. G., Zhu, C., Wang, L., Tariq, I., Kamath, G. M., Simoes, R. D., Dhimolea, E., ... Mitsiades, C. S. (2021). Genome-scale screens identify factors regulating tumor cell responses to natural killer cells. Nature Genetics, 53(8), 1196-1206. https://doi.org/10.1038/s41588-021-00889-wMeer informative over deze publicatie
-
Ehlers, F. A., Beelen, N. A., van Gelder, M., Evers, T. M. J., Smidt, M. L., Kooreman, L. F. S., Bos, G. M. J., & Wieten, L. (2021). ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response. Cancers, 13(13), Article 3232. https://doi.org/10.3390/cancers13133232Meer informative over deze publicatie